{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:32:03Z","timestamp":1793943123019,"version":"4.8.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10875-023-01519-2","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T05:02:05Z","timestamp":1685336525000},"page":"1182-1184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Successful Rezafungin Treatment of an Azole-Resistant Chronic Mucocutaneous Candidiasis in a STAT-1 Gain-of-Function Patient"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3159-1061","authenticated-orcid":false,"given":"Cl\u00e9a","family":"Melenotte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Ratiney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Elisabeth","family":"Bougnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Lanternier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"key":"1519_CR1","doi-asserted-by":"crossref","unstructured":"van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LAB, Gilissen C, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous Candidiasis. N Engl J Med [Internet]. 2011 [cited 2022 Nov 13];365:54\u201361. http:\/\/www.nejm.org\/doi\/abs\/10.1056\/NEJMoa1100102","DOI":"10.1056\/NEJMoa1100102"},{"key":"1519_CR2","doi-asserted-by":"crossref","unstructured":"Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood [Internet]. 2016 [cited 2022 Nov 13];127:3154\u201364. https:\/\/ashpublications.org\/blood\/article\/127\/25\/3154\/35201\/Heterozygous-STAT1-gainoffunction-mutations","DOI":"10.1182\/blood-2015-11-679902"},{"key":"1519_CR3","unstructured":"Liu L, Okada S, Kong X-F, Kreins AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous Candidiasis. J Exp Med [Internet]. 2011 [cited 2022 Nov 13];208:1635\u201348. https:\/\/rupress.org\/jem\/article\/208\/8\/1635\/41136\/Gainoffunction-human-STAT1-mutations-impair-IL17"},{"key":"1519_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s10875-022-01351-0","volume":"43","author":"EW Borgstr\u00f6m","year":"2023","unstructured":"Borgstr\u00f6m EW, Edvinsson M, P\u00e9rez LP, Norlin AC, Enoksson SL, Hansen S, et al. Three adult cases of STAT1 gain-of-function with chronic mucocutaneous Candidiasis treated with JAK inhibitors. J Clin Immunol. 2023;43:136\u201350.","journal-title":"J Clin Immunol"},{"key":"1519_CR5","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","volume":"81","author":"M Hoenigl","year":"2021","unstructured":"Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;81:1703\u201329.","journal-title":"Drugs"},{"key":"1519_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","volume":"401","author":"GR Thompson","year":"2023","unstructured":"Thompson GR, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, et al. Rezafungin versus caspofungin for treatment of candidaemia and invasive Candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023;401:49\u201359.","journal-title":"Lancet"},{"key":"1519_CR7","doi-asserted-by":"publisher","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","volume":"73","author":"GR Thompson","year":"2021","unstructured":"Thompson GR, Soriano A, Skoutelis A, Vazquez JA, Honore PM, Horcajada JP, et al. Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive Candidiasis: the STRIVE trial. Clin Infect Dis. 2021;73:e3647\u201355.","journal-title":"Clin Infect Dis"},{"key":"1519_CR8","doi-asserted-by":"crossref","unstructured":"Coste AT, Kritikos A, Li J, Khanna N, Goldenberger D, Garzoni C, et al. Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland. Infection [Internet]. 2020 [cited 2022 Nov 15];48:761\u20136. https:\/\/link.springer.com\/10.1007\/s15010-020-01475-8","DOI":"10.1007\/s15010-020-01475-8"},{"key":"1519_CR9","doi-asserted-by":"crossref","unstructured":"Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. Journal of Antimicrobial Chemotherapy [Internet]. 2018 [cited 2022 Nov 15];73:i4\u201313. http:\/\/academic.oup.com\/jac\/article\/73\/suppl_1\/i4\/4769692","DOI":"10.1093\/jac\/dkx444"},{"key":"1519_CR10","doi-asserted-by":"publisher","first-page":"7465","DOI":"10.1128\/AAC.01973-15","volume":"59","author":"RK Shields","year":"2015","unstructured":"Shields RK, Nguyen MH, Press EG, Cumbie R, Driscoll E, Pasculle AW, et al. Rate of FKS mutations among consecutive Candida isolates causing bloodstream infection. Antimicrob Agents Chemother. 2015;59:7465\u201370.","journal-title":"Antimicrob Agents Chemother"},{"key":"1519_CR11","doi-asserted-by":"publisher","first-page":"e0172521","DOI":"10.1128\/aac.01725-21","volume":"66","author":"M Desnos-Ollivier","year":"2022","unstructured":"Desnos-Ollivier M, Bretagne S, Lortholary O, Dromer F, French Mycoses Study Group N. Brieu CH Aix, T. Chouaki , C. Damiani , A. Totet CHU Amiens, J. P. Bouchara , D. Chabasse , M. Pihet CHU Angers, S. Bland CH Annecy, V. Blanc CH Antibes, S. Branger CH Avignon, A. P. Bellanger , L. Millon CHU Besan\u00e7on, C. Plassart CH Beauvais, I. PoilaneH\u00f4pital Jean Verdier, Bondy, I. Accoceberry , L. Delhaes , B. Couprie , F. Gabriel CH Bordeaux, J. Dunand , A. L. Roux , V. Sivadon-Tardy H\u00f4pitalAmbroisePar\u00e9, Boulogne Billancourt, F. Laurent CH, Bourg enBresse, S. Legal , E. Moalic , G. Nevez , D. Quinio CHU Brest, M. Cariou CH Bretagne Sud, J. Bonhomme , C. Duhamel CHU, Caen, B. Podac CH, Chalon sur Sa\u00f4ne, S. Lechatch CH, Charleville-M\u00e9zi\u00e8res, C. Soler Hopitald\u2019Instruction des arm\u00e9es, Clamart, M. Cambon , C. Nourrisson , P. Poirier , D. Pons CHU, Clermont Ferrand, O. Augereau , I. Grawey CH, Colmar, N. Fauchet CHIC, Cr\u00e9teil, A. Bonnin , F. Dalle CHU, Dijon, P. Cahen , P. Honderlick CMC, Foch, N. Desbois , C. Miossec CHU, Fort de France, J. L. Hermann H\u00f4pital Raymond Poincar\u00e9, Garches, M. Cornet , R. Grillot , B. Lebeau , D. Maubon , H. Pelloux CHU, Grenoble, M. Nicolas CHU, Guadeloupe, C. Aznar , D. Blanchet , J. F. Carod , M. Demar CHU, Guyane, A. AngoulvantH\u00f4pitalBic\u00eatre, le Kremlin Bic\u00eatre, C. Ciupek CH, Le Mans, A. GigandonH\u00f4pital Marie Lannelongue, Le Plessis Robinson, B. Bouteille CH Limoges, E. Frealle , D. Poulain , B. Sendid CHU Lille, D. Dupont , J. Menotti , F. Persat , M.-A. Piens , M. Wallon CHU, Lyon, C. Cassagne , S. Ranque CHU, Marseille, T. Benoit-Cattin , L. Collet CH Mayotte, A. Fiacre CH Meaux, N. Bourgeois , L. Lachaud , P. Rispail , Y. Sterkers CHU, Montpellier, M. Machouart CHU, Nancy, F. Gay-Andrieu , P. Lepape , F. Morio CHU, Nantes, O. Moquet CH, Nevers, S. Lefran\u00e7oisH\u00f4pitalAm\u00e9ricain, Neuilly, M. Sasso CHU, Nimes, F. Reibel GH, Nord-Essone, M. Gari-Toussaint , L. Hasseine CHU Nice, L. Bret , D. Poisson CHR Orl\u00e9ans, S. BrunH\u00f4pitalAvicenne, Paris, C. Bonnal , C. Chochillon , S. Houz\u00e9H\u00f4pital Bichat, Paris, A. PaugamH\u00f4pital Cochin, Paris, N. Ait-Ammar , F. Botterel , R. Chouk CHU Henri Mondor, Paris, M. E. Bougnoux , E. SitterleH\u00f4pital Necker, Paris, A. Fekkar , R. PiarrouxH\u00f4pitalPiti\u00e9Salp\u00eatri\u00e8re, Paris, J. Guitard , C. Hennequin , J.-L. PoirotH\u00f4pital St Antoine, Paris, M. Gits-Muselli , S. Hamane , C. Lacroix H\u00f4pital Saint Louis, Paris, S. Bonacorsi , P. MarianiH\u00f4pital Robert Debr\u00e9, Paris, D. MoissenetH\u00f4pital Trousseau, Paris, C. Kauffmann-Lacroix , A. Minoza , E. Perraud , M. H. Rodier CHU Poitiers, G. Colonna CH, Porto Vecchio, A. Huguenin , D. Toubas CHU Reims, S. Chevrier , J. P. Gangneux , F. Robert-Gangneux , C. Guigen CHU Rennes, O. Belmonte , G. Hoarau , M. C. JaffarBandjee , J. Jaubert , S. Picot , N. Traversier CHU R\u00e9union, L. Favennec , G. Gargala CHU, Rouen, N. Godineau , C. Tournus CH, St Denis, C. Mahinc , H. Raberin CHU, St Etienne, V. LetscherBru CHU, Strasbourg, S. Cassaing CHU, Toulouse, P. Patoz CH Tourcoing, E. Bailly , J. Chandenier , G. Desoubeaux CHU Tours, F. Moreau CH Troyes, P. Munier CH Valence, E. Mazars CH Valenciennes, O. Eloy CH Versailles, ChachatyInstitut Gustave Roussy E, Villejuif. Echinocandins susceptibility patterns of 2,787 yeast isolates: importance of the thresholds for the detection of FKS mutations. Antimicrob Agents Chemother. 2022;66:e0172521.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01519-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-023-01519-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01519-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T07:16:04Z","timestamp":1689664564000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-023-01519-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1519"],"URL":"https:\/\/doi.org\/10.1007\/s10875-023-01519-2","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,29]]},"assertion":[{"value":"11 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed and written consent was obtained from the patient for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from the patient to received compassionate drug.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Informed and written consent was obtained from the patient for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}